Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CHMP backs pomalidomide, lomitapide

EMA's CHMP backed approval of pomalidomide from Celgene Corp. (NASDAQ:CELG) to treat patients

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE